Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations

@article{Dedes2011SyntheticLO,
  title={Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations},
  author={Konstantin J. Dedes and Paul M. Wilkerson and D Wetterskog and Britta Weigelt and Alan Ashworth and Jorge Sergio Reis-Filho},
  journal={Cell Cycle},
  year={2011},
  volume={10},
  pages={1192 - 1199}
}
Utilizing the concept of synthetic lethality has provided new opportunities for the development of targeted therapies, by allowing the targeting of loss of function genetic aberrations. In cancer cells with BRCA1 or BRCA2 loss of function, which harbor deficiency of DNA repair by homologous recombination, inhibition of PARP1 enzymatic activity leads to an accumulation of single strand breaks that are converted to double strand breaks but cannot be repaired by homologous recombination… Expand
Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
TLDR
The results in HR-proficient cell lines suggest that PARP1-i combined with thermochemotherapy can be a promising clinical approach for all tumors independent of HR status. Expand
Epigenetic based synthetic lethal strategies in human cancers
TLDR
The paradigm study is to induce cell death by inhibiting PARP in BRCA1/2 defective cells, and a growing number of developed DDR inhibitors are ongoing in preclinical and clinical testing, including ATM, ATR, CHK 1/2 and WEE1 inhibitors. Expand
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
TLDR
A functional test to determine HR activity in tumor samples is developed and has clear advantages over gene sequencing, making it a powerful tool to select patients with an HR-deficient cancer for PARP inhibitor treatment in the clinic. Expand
BRCA1-directed, enhanced and aberrant homologous recombination
TLDR
Recent findings of how altered functions of these domains might lead to cancer through a mechanism of increased aberrant homologous recombination are reviewed and possible implications for the development of BRCA1 inhibitors are reviewed. Expand
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
TLDR
The results show that ARID1A is essential for establishing an open chromatin state upon DNA damage, a process required for recruitment of 53BP1 and RIF1, key mediators of non-homologous end-joining (NHEJ) machinery, to DNA lesions, and suggest a novel biologically informed strategy for treating ARid1A-deficient malignancies. Expand
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells
TLDR
It is suggested that a combi-molecular approach directed at blocking PARP and damaging DNA can lead to single molecules with selective and enhanced potency against BRCA1/2 mutant and with activity independent of MGMT, the major predictive biomarker for resistance to TMZ. Expand
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
  • A. Ratanaphan
  • Biology, Medicine
  • International journal of molecular sciences
  • 2012
TLDR
Initial findings indicate that neoadjuvant use of cisplatin results in high rates of complete pathological response in patients with breast cancer who have BRCA1 mutations, which implies that TNBC cells may harbor a dysfunctional BRCa1 repair pathway. Expand
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
TLDR
This study helps characterize genetic and functional determinants of cellular responses to PARP-1i and contributes to the search for biomarkers to exploit PARP inhibitors in cancer therapy. Expand
Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.
TLDR
This review focuses on the outcomes of the combined action of PARP-1 inhibitors and agents that affect the activity of DNA topoisomerases. Expand
Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
TLDR
The concept of BRCAness is explored and the different methods that have been used to identify patients who may benefit from the use of these anticancer agents are highlighted and the identification of predictive biomarkers for PARPi therapy is highlighted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
TLDR
The results suggest that DNA repair pathways other than HR may determine sensitivity to PARP inhibitors and highlight the likelihood that ostensibly distinct DNA Repair pathways cooperate to maintain genomic stability and cellular viability. Expand
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
TLDR
The data presented here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours. Expand
Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer
TLDR
It is demonstrated that CRC cell lines with HRD due to MRE11 mutation and loss of protein expression are highly sensitive to the PARP inhibitor olaparib, providing evidence that patients with MSI and MRE 11‐deficient colorectal tumors could be suitable for treatment with olapARib. Expand
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
TLDR
BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage. Expand
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
TLDR
The authors demonstrate that endometrial cancer cell lines that lack the tumor suppressor protein PTEN show defects in the repair of DNA damage and are consequently very sensitive to drugs that block poly(ADP) ribose polymerase (PARP), an enzyme critical for DNA repair. Expand
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
TLDR
It is proposed that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair and exploited in order to kill BRCA2-deficient tumours by PARP inhibition alone. Expand
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
TLDR
The results indicate that PARP inhibition might be a useful therapeutic strategy not only for the treatment of BRCA mutation-associated tumors but also for a wider range of tumors bearing a variety of deficiencies in the HR pathway or displaying properties of 'BRCAness. Expand
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
TLDR
It is suggested that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy. Expand
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
TLDR
It is shown that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function. Expand
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
TLDR
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation. Expand
...
1
2
3
4
5
...